Issue Date: October 28, 2013
AstraZeneca Signs Two Research Pacts
AstraZeneca will team up on drug R&D with two organizations. German drug discovery firm Evotec will provide AstraZeneca with molecules that might be effective against chronic kidney diseases. AstraZeneca is making an up-front payment to Evotec and could make milestone payments. In Taiwan, AstraZeneca has joined with the National Research Program for Biopharmaceuticals, a government-funded drug discovery organization. NRPB will work with research groups in Taiwan to find alternative therapeutic uses for existing AstraZeneca compounds.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society